Oxytrol for Women is a Transdermal Patch in the Human Otc Drug category. It is labeled and distributed by Allergan, Inc.. The primary component is Oxybutynin.
Product ID | 0023-9637_15e35837-8b6f-44e6-a5f5-00d32c6a32c0 |
NDC | 0023-9637 |
Product Type | Human Otc Drug |
Proprietary Name | Oxytrol for Women |
Generic Name | Oxybutynin |
Dosage Form | Patch |
Route of Administration | TRANSDERMAL |
Marketing Start Date | 2016-01-01 |
Marketing Category | NDA / NDA |
Application Number | NDA202211 |
Labeler Name | Allergan, Inc. |
Substance Name | OXYBUTYNIN |
Active Ingredient Strength | 4 mg/d |
NDC Exclude Flag | N |
Listing Certified Through | 2020-12-31 |
Marketing Start Date | 2016-01-01 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA202211 |
Product Type | HUMAN OTC DRUG |
Billing Unit | EA |
Marketing Start Date | 2019-10-01 |
Marketing Category | NDA |
Application Number | NDA202211 |
Product Type | HUMAN OTC DRUG |
Billing Unit | EA |
Marketing Start Date | 2016-01-01 |
Ingredient | Strength |
---|---|
OXYBUTYNIN | 3.9 mg/d |
SPL SET ID: | 8cdc5b4d-ff8d-4010-97d7-313422a0b868 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
0023-9637 | Oxytrol for Women | Oxybutynin |
52544-166 | Oxytrol For Women | oxybutynin |
0615-8219 | oxybutynin | oxybutynin |
0615-8220 | Oxybutynin | Oxybutynin |
50090-5352 | oxybutynin | oxybutynin |
50090-5353 | oxybutynin | oxybutynin |
68382-255 | oxybutynin | oxybutynin |
68382-256 | oxybutynin | oxybutynin |
68382-257 | oxybutynin | oxybutynin |
70518-1457 | oxybutynin | oxybutynin |
70518-2331 | oxybutynin | oxybutynin |
70771-1086 | oxybutynin | oxybutynin |
70771-1087 | oxybutynin | oxybutynin |
70771-1088 | oxybutynin | oxybutynin |
71335-0974 | oxybutynin | oxybutynin |
0023-6153 | OXYTROL | Oxybutynin |
52544-920 | OXYTROL | Oxybutynin |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
OXYTROL FOR WOMEN 85968346 4594119 Live/Registered |
Actavis, Inc. 2013-06-24 |